BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ story “gaining traction over the next 12 months” and cites slightly reduced outer-year revenue expectations, offset by reduced expenses, for its revised target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- AGIO Upcoming Earnings Report: What to Expect?
- Agios Pharma Sets Milestones for Rare Disease Growth
- Agios Pharmaceuticals announces key 2025 milestones, catalysts through 2026
- Agios Pharmaceuticals announces FDA accepted sNDA for PYRUKYND
- Agios Pharmaceuticals price target lowered to $55 from $60 at BofA